Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T06:15:29.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed information about a clinical trial for Sacituzumab Govitecan and Pembrolizumab, while adding new collaborators and a revision number. Notably, the core content regarding the study's procedures and eligibility criteria has been deleted.
    Difference
    48%
    Check dated 2025-04-16T20:27:55.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T13:31:55.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-02T00:05:36.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T22:51:00.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T16:07:11.000Z thumbnail image

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.